MA34771B1 - Formes cristallines - Google Patents
Formes cristallinesInfo
- Publication number
- MA34771B1 MA34771B1 MA36066A MA36066A MA34771B1 MA 34771 B1 MA34771 B1 MA 34771B1 MA 36066 A MA36066 A MA 36066A MA 36066 A MA36066 A MA 36066A MA 34771 B1 MA34771 B1 MA 34771B1
- Authority
- MA
- Morocco
- Prior art keywords
- varieties
- modulation
- sensitive
- cells
- determining
- Prior art date
Links
- 108091008794 FGF receptors Proteins 0.000 title 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 title 1
- 210000004027 cell Anatomy 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- -1 piperidin-4-ylphenyl Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424194P | 2010-12-17 | 2010-12-17 | |
| PCT/US2011/065030 WO2012082972A1 (en) | 2010-12-17 | 2011-12-15 | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34771B1 true MA34771B1 (fr) | 2013-12-03 |
Family
ID=45464892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36066A MA34771B1 (fr) | 2010-12-17 | 2013-06-28 | Formes cristallines |
Country Status (36)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3121171B1 (en) | 2010-12-17 | 2018-08-15 | Novartis Ag | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
| CN104854101B (zh) | 2012-11-06 | 2018-05-01 | 上海复尚慧创医药研究有限公司 | Alk激酶抑制剂 |
| KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| CN105272921A (zh) * | 2014-06-09 | 2016-01-27 | 江苏奥赛康药业股份有限公司 | 一种制备Ceritinib的方法及其中间体化合物 |
| CN105294649B (zh) * | 2014-07-30 | 2019-05-14 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| CN105294650A (zh) * | 2014-08-01 | 2016-02-03 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| CN111888368B (zh) | 2014-10-21 | 2024-02-02 | 武田药品工业株式会社 | 5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形 |
| WO2016081538A1 (en) | 2014-11-18 | 2016-05-26 | Teva Pharmaceuticals International Gmbh | Solid state forms of ceritinib and salts thereof |
| CN105601614A (zh) * | 2014-11-21 | 2016-05-25 | 奥浦顿（上海）医药科技有限公司 | 一种色瑞替尼晶型及其制备方法 |
| WO2016082795A1 (zh) * | 2014-11-28 | 2016-06-02 | 苏州晶云药物科技有限公司 | 色瑞替尼的晶型i及其制备方法 |
| CN105622577A (zh) * | 2014-11-29 | 2016-06-01 | 江苏先声药业有限公司 | 一种色瑞替尼的新晶型及其制备方法 |
| WO2016108123A2 (en) * | 2014-12-17 | 2016-07-07 | Dr. Reddy’S Laboratories Limited | Pure amorphous and amorphous solid dispersion of ceritinib |
| WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
| WO2016098042A1 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders |
| EP3328848A1 (en) | 2015-07-28 | 2018-06-06 | Zentiva, K.S. | Solid forms of ceritinib free base |
| CN105061397B (zh) * | 2015-08-07 | 2018-01-02 | 武汉英普瑞医药科技有限公司 | 一种色瑞替尼的c型晶型及其制备方法与应用 |
| CN106699743B (zh) | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
| WO2017152858A1 (zh) * | 2016-03-11 | 2017-09-14 | 苏州晶云药物科技有限公司 | 色瑞替尼的晶型及其制备方法 |
| WO2017158619A1 (en) | 2016-03-15 | 2017-09-21 | Natco Pharma Limited | A modified process for the preparation of ceritinib and amorphous form of ceritinib |
| JP2019196359A (ja) * | 2019-06-17 | 2019-11-14 | ノバルティス アーゲー | ピリミジン誘導体およびそれらの中間体を調製する化学的方法 |
| GB201915618D0 (en) | 2019-10-28 | 2019-12-11 | Univ Oslo | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
| EP4092021B1 (en) | 2020-01-17 | 2025-11-12 | Xuanzhu Biopharmaceutical Co., Ltd. | Crystal form of polycyclic anaplastic lymphoma kinase inhibitor |
| KR20230008047A (ko) * | 2020-03-30 | 2023-01-13 | 장슈 야홍 메디텍 코퍼레이션 리미티드 | 니트록솔린 전구약물의 결정 형태, 이를 함유하는 약학 조성물, 및 이의 제조 방법 및 이의 용도 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| SI2287156T1 (sl) * | 2003-08-15 | 2013-09-30 | Novartis Ag | 2,4-di(fenilamino)-pirimidini, uporabni pri zdravljenju neoplastičnih bolezni, vnetnih motenj in motenj imunskega sistema |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| EP2311807B1 (en) | 2006-12-08 | 2015-11-11 | Novartis AG | Compounds and composition as protein kinase inhibitors |
| WO2008073687A2 (en) * | 2006-12-08 | 2008-06-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| BRPI0815979A2 (pt) * | 2007-08-28 | 2017-06-13 | Irm Llc | compostos e composições com inibidores de quinase, bem como uso dos mesmos |
| WO2009032703A1 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| KR101238585B1 (ko) | 2008-04-07 | 2013-02-28 | 노파르티스 아게 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| PL2300013T5 (pl) * | 2008-05-21 | 2025-04-28 | Takeda Pharmaceutical Company Limited | Pochodne fosforu jako inhibitor kinazy |
| US20120142667A1 (en) * | 2009-06-10 | 2012-06-07 | Nigel Ramsden | Pyrimidine derivatives as zap-70 inhibitors |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| KR102000301B1 (ko) | 2010-12-17 | 2019-07-15 | 리아타 파마슈티컬즈, 아이엔씨. | 산화방지성 염증 조절제로서의 피라졸릴 및 피리미디닐 트리사이클릭 엔온 |
| JP2014501246A (ja) | 2010-12-17 | 2014-01-20 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 殺菌・殺カビ性アゾ環式アミド |
| EP3121171B1 (en) | 2010-12-17 | 2018-08-15 | Novartis Ag | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
| CN105294650A (zh) | 2014-08-01 | 2016-02-03 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| WO2016081538A1 (en) | 2014-11-18 | 2016-05-26 | Teva Pharmaceuticals International Gmbh | Solid state forms of ceritinib and salts thereof |
| DE112015005255B4 (de) | 2014-11-21 | 2023-10-26 | Joyson Safety Systems Acquisition Llc | Airbagmodul |
| CN105622577A (zh) | 2014-11-29 | 2016-06-01 | 江苏先声药业有限公司 | 一种色瑞替尼的新晶型及其制备方法 |
| KR20170088984A (ko) | 2014-12-04 | 2017-08-02 | 브리스톨-마이어스 스큅 컴퍼니 | 암 (골수종)을 치료하기 위한 항-cs1 항체와 항-pd1 항체의 조합 |
| WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
| EP3328848A1 (en) | 2015-07-28 | 2018-06-06 | Zentiva, K.S. | Solid forms of ceritinib free base |
| CN105061397B (zh) | 2015-08-07 | 2018-01-02 | 武汉英普瑞医药科技有限公司 | 一种色瑞替尼的c型晶型及其制备方法与应用 |
-
2011
- 2011-12-15 EP EP16167355.3A patent/EP3121171B1/en active Active
- 2011-12-15 CN CN201710063792.0A patent/CN106831716A/zh active Pending
- 2011-12-15 SG SG2013039342A patent/SG190856A1/en unknown
- 2011-12-15 WO PCT/US2011/065030 patent/WO2012082972A1/en not_active Ceased
- 2011-12-15 SG SG10201510082XA patent/SG10201510082XA/en unknown
- 2011-12-15 PE PE2013001425A patent/PE20140698A1/es not_active Application Discontinuation
- 2011-12-15 DK DK16167355.3T patent/DK3121171T3/en active
- 2011-12-15 AR ARP110104703A patent/AR084309A1/es not_active Application Discontinuation
- 2011-12-15 RS RS20181240A patent/RS57771B1/sr unknown
- 2011-12-15 CN CN201610217386.0A patent/CN106008462A/zh active Pending
- 2011-12-15 CN CN201710063793.5A patent/CN107056751A/zh active Pending
- 2011-12-15 US US13/993,217 patent/US9309229B2/en active Active
- 2011-12-15 ES ES16167355T patent/ES2696526T3/es active Active
- 2011-12-15 KR KR1020187007996A patent/KR20180032680A/ko not_active Ceased
- 2011-12-15 PT PT118060797T patent/PT2651918T/pt unknown
- 2011-12-15 DK DK11806079.7T patent/DK2651918T3/en active
- 2011-12-15 BR BR112013015000A patent/BR112013015000A2/pt not_active Application Discontinuation
- 2011-12-15 RU RU2013132947A patent/RU2599785C3/ru active Protection Beyond IP Right Term
- 2011-12-15 RU RU2016136823A patent/RU2746159C2/ru active
- 2011-12-15 MX MX2013006952A patent/MX338210B/es active IP Right Grant
- 2011-12-15 KR KR1020137018605A patent/KR20130130022A/ko not_active Withdrawn
- 2011-12-15 CN CN201410457562.9A patent/CN104262324A/zh active Pending
- 2011-12-15 CN CN202210792464.5A patent/CN114989139A/zh active Pending
- 2011-12-15 JP JP2013544762A patent/JP5916752B2/ja active Active
- 2011-12-15 ES ES18186197T patent/ES2905973T3/es active Active
- 2011-12-15 LT LTEP16167355.3T patent/LT3121171T/lt unknown
- 2011-12-15 MY MYPI2016001551A patent/MY177742A/en unknown
- 2011-12-15 KR KR1020207009828A patent/KR102325775B1/ko active Active
- 2011-12-15 AU AU2011343775A patent/AU2011343775B2/en active Active
- 2011-12-15 PL PL16167355T patent/PL3121171T3/pl unknown
- 2011-12-15 LT LTEP11806079.7T patent/LT2651918T/lt unknown
- 2011-12-15 CN CN202011050061.0A patent/CN112125884A/zh active Pending
- 2011-12-15 ES ES11806079.7T patent/ES2643016T3/es active Active
- 2011-12-15 NZ NZ610713A patent/NZ610713A/en not_active IP Right Cessation
- 2011-12-15 CA CA2821102A patent/CA2821102C/en active Active
- 2011-12-15 PL PL11806079T patent/PL2651918T3/pl unknown
- 2011-12-15 PH PH1/2013/501254A patent/PH12013501254A1/en unknown
- 2011-12-15 CN CN201180060435XA patent/CN103282359A/zh active Pending
- 2011-12-15 EP EP11806079.7A patent/EP2651918B1/en not_active Revoked
- 2011-12-15 EP EP18186197.2A patent/EP3453708B8/en active Active
- 2011-12-15 SI SI201131289T patent/SI2651918T1/sl unknown
- 2011-12-15 SI SI201131583T patent/SI3121171T1/sl unknown
- 2011-12-15 HU HUE16167355A patent/HUE041845T2/hu unknown
- 2011-12-15 KR KR1020197005138A patent/KR20190022903A/ko not_active Ceased
- 2011-12-15 MY MYPI2013001848A patent/MY164810A/en unknown
- 2011-12-15 HR HRP20171477TT patent/HRP20171477T1/hr unknown
- 2011-12-15 PT PT16167355T patent/PT3121171T/pt unknown
- 2011-12-16 TW TW105112710A patent/TWI576344B/zh active
- 2011-12-16 TW TW100146987A patent/TWI576343B/zh active
-
2013
- 2013-05-17 TN TNP2013000216A patent/TN2013000216A1/fr unknown
- 2013-05-17 ZA ZA2013/03599A patent/ZA201303599B/en unknown
- 2013-05-20 IL IL226474A patent/IL226474A/en active IP Right Grant
- 2013-06-14 CL CL2013001723A patent/CL2013001723A1/es unknown
- 2013-06-17 GT GT201300153A patent/GT201300153A/es unknown
- 2013-06-28 MA MA36066A patent/MA34771B1/fr unknown
- 2013-07-04 CO CO13158446A patent/CO6801792A2/es not_active Application Discontinuation
- 2013-07-16 EC ECSP13012770 patent/ECSP13012770A/es unknown
-
2016
- 2016-03-02 US US15/058,489 patent/US20160175305A1/en not_active Abandoned
-
2017
- 2017-10-11 CY CY20171101064T patent/CY1119474T1/el unknown
-
2018
- 2018-10-22 HR HRP20181737TT patent/HRP20181737T1/hr unknown
- 2018-11-09 CY CY181101192T patent/CY1121017T1/el unknown
-
2021
- 2021-03-19 AR ARP210100698A patent/AR122395A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34771B1 (fr) | Formes cristallines | |
| MA32351B1 (fr) | Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer | |
| EP2410330A3 (en) | Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual | |
| TW200634006A (en) | Tetrahydroquinoline analogues as muscarinic agonists | |
| MA34299B1 (fr) | Dérivés d'aminopyrimidine au titre de modulateurs de lrrk2 | |
| MA34069B1 (fr) | Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a) | |
| EA200970612A1 (ru) | Производные индола в качестве агонистов рецептора s1p1 | |
| MA30672B1 (fr) | Utilisation de derives de l'azabicyclo hexane | |
| TW200621722A (en) | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds | |
| EA201070148A1 (ru) | Соединения и способы модулирования фарнезоидного рецептора x (fxr) | |
| EA200800727A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
| MA32471B1 (fr) | Composés de borates esters et compositions pharmaceutiques contenant des composés | |
| MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
| WO2009155054A3 (en) | 5-ht3 receptor modulators, methods of making, and use thereof | |
| EP1740559A4 (en) | ALSHEETS INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE SUITABLE 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| MA39972B1 (fr) | Composés et compositions d'induction de la chondrogenèse | |
| MA39163A1 (fr) | Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine | |
| WO2006102308A3 (en) | Beta-lactamyl vasopressin v1b antagonists | |
| MA39164A1 (fr) | Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine | |
| MX2012000572A (es) | Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos. | |
| HK1255438A1 (zh) | 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 | |
| UA83868C2 (ru) | Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1 | |
| EA201071309A1 (ru) | Твердая фармацевтическая композиция | |
| EA200970432A1 (ru) | 8-сульфонил-1,3,4,8-тетрагидро-2н-[1,4]оксазепино[6,7-e] индольные производные и их использование в качестве 5-нт6 рецепторных лигандов |